investor
Galapagos Investor Seeks to Influence Company Control, Citing Undervaluation
Galapagos, investor influence, undervaluation, biotech, corporate control
Biotech IPO Market Sees Shifts in Funding and Investor Appetite
biotech IPOs, crossover funding, venture capital, clinical-stage assets, market correction, investor demand
Gene Editing Biotech Tome Scales Back Operations Despite $213M Funding Round
Gene editing, biotech, Tome, funding, investor sentiment, layoffs, reorganization
Biohaven’s Phase I Data for Lead Protein Degrader Falls Short of Investor Expectations ###
Biohaven, BHV-1300, Protein degrader, IgG reduction, Phase I study, Investor expectations, Autoimmune disorders, Rheumatoid arthritis, Myasthenia gravis
Merus’ Bispecific Antibody Therapy Shows Promising Early Results in Cancer Treatment
Merus, bispecific antibody, cancer treatment, early results, investor expectations, ASCO
Groundbreaking Data Revealed for Genetic Epilepsy Drug STK-001 by Stoke Therapeutics, Exhilarating Investors
Stoke Therapeutics, STK-001, Genetic Epilepsy Drug, Dravet Syndrome, Antisense Oligonucleotide, Seizure Reduction, Positive Clinical Trial Data, Investor Enthusiasm
Bayer Acquires European Rights to BridgeBio’s Acoramidis for ATTR-CM Therapy
Bayer, BridgeBio Pharma, Acoramidis, ATTR-CM, Exclusive License, European Rights, Royalties, Milestone Payments, Phase 3 Data, Potential Approval, Low-Thirties Percent Royalties, EMA Approval 2025, PDUFA Action Date November 2024, Vyndaqel Rival, Blockbuster Potential, Cardiovascular Infrastructure, Investor Hopes for Clarity on Split Strategy.